SciCombinator

Discover the most talked about and latest scientific content & concepts.

Case reports study of the first five patients COVID-19 treated with remdesivir in France

OPEN International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 4 Jul 2020

M Dubert, B Visseaux, V Isernia, L Bouadma, L Deconinck, J Patrier, PH Wicky, D Le Pluart, L Kramer, C Rioux, Q Le Hingrat, N Houhou-Fidouh, Y Yazdanpanah, J Ghosn and FX Lescure
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as responsible for the COVID-19 outbreak worldwide. Data on treatment are scare and parallels are made between SARS-CoV-2 and other coronavirus. Remdesivir is a broad spectrum antiviral with efficient in vitro activity against SARS-CoV-2 and controversial evidence of clinical improvement in severe COVID-19 patients. We aimed to describe the clinical outcome and virological monitoring of the first five COVID-19 patients admitted in ICU for severe pneumonia related to SARS-CoV-2 and treated with remdesivir in the University hospital of Bichat, Paris, France. SARS-CoV-2 RT-qPCR in blood plasma, lower and upper respiratory tract were monitored. Among the five treated patients, two needed mechanical ventilation and one high flow cannula oxygen. A significant decrease in SARS-CoV-2 viral load from upper respiratory tract was observed in most cases but two died with active SARS-CoV-2 replication in the lower respiratory tract. Plasma samples were positive for SARS-CoV-2 in only one patient. Remdesivir was interrupted for side effects among four patients, including 2 ALT elevations (3 to 5‚ÄČN) and 2 renal failures requiring renal replacement. This case series of five COVID-19 patients requiring ICU for a respiratory distress and treated with remdesivir, highlights the complexity of remdesivir use in such critically ill patients.
Tweets*
11933
Facebook likes*
1
Reddit*
0
News coverage*
3
Blogs*
0
SC clicks
0
Concepts
-
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com